Acta Pharmaceutica Sinica B,
Journal Year:
2020,
Volume and Issue:
11(1), P. 222 - 236
Published: Oct. 10, 2020
Lianhuaqingwen
(LHQW)
capsule,
a
herb
medicine
product,
has
been
clinically
proved
to
be
effective
in
coronavirus
disease
2019
(COVID-19)
pneumonia
treatment.
However,
human
exposure
LHQW
components
and
their
pharmacological
effects
remain
largely
unknown.
Hence,
this
study
aimed
determine
anti-COVID-19
activities.
Analysis
of
component
profiles
plasma
urine
after
repeated
therapeutic
dosing
was
conducted
using
combination
HRMS
an
untargeted
data-mining
approach,
leading
detection
132
prototype
metabolite
components,
which
were
absorbed
via
the
gastrointestinal
tract
formed
biotransformation
human,
respectively.
Together
with
data
from
screening
by
comprehensive
2D
angiotensin-converting
enzyme
2
(ACE2)
biochromatography,
8
that
exposed
had
potential
ACE2
targeting
ability
identified
for
further
pharmacodynamic
evaluation.
Results
show
rhein,
forsythoside
A,
I,
neochlorogenic
acid
its
isomers
exhibited
high
inhibitory
effect
on
ACE2.
For
first
time,
provides
chemical
biochemical
evidence
exploring
molecular
mechanisms
capsule
treatment
COVID-19
patients
based
human.
It
also
demonstrates
utility
exposure-based
approach
identify
pharmaceutically
active
Chinese
medicines.
Cell Reports,
Journal Year:
2020,
Volume and Issue:
32(3), P. 107940 - 107940
Published: July 1, 2020
Severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
is
the
causative
agent
of
novel
viral
disease
COVID-19.
With
no
approved
therapies,
this
pandemic
illustrates
urgent
need
for
broad-spectrum
antiviral
countermeasures
against
SARS-CoV-2
and
future
emerging
CoVs.
We
report
that
remdesivir
(RDV)
potently
inhibits
replication
in
human
lung
cells
primary
airway
epithelial
cultures
(EC50
=
0.01
μM).
Weaker
activity
observed
Vero
E6
1.65
μM)
because
their
low
capacity
to
metabolize
RDV.
To
rapidly
evaluate
vivo
efficacy,
we
engineered
a
chimeric
SARS-CoV
encoding
target
RDV,
RNA-dependent
RNA
polymerase
SARS-CoV-2.
In
mice
infected
with
virus,
therapeutic
RDV
administration
diminishes
load
improves
pulmonary
function
compared
vehicle-treated
animals.
These
data
demonstrate
active
vitro
vivo,
supporting
its
further
clinical
testing
treatment
Journal of Traditional and Complementary Medicine,
Journal Year:
2020,
Volume and Issue:
10(4), P. 420 - 427
Published: May 30, 2020
A
novel
coronavirus
disease
(COVID-19),
transmitted
from
humans
to
humans,
has
rapidly
become
the
pandemic
responsible
for
current
global
health
crisis.
COVID-19
is
caused
by
severe
acute
respiratory
syndrome
2
(SARS-CoV-2),
which
said
be
of
zoonotic
origin.
This
review
describes
etiology
and
signs
symptoms
as
well
allopathic
therapy
COVID-19.
Additionally,
findings
previous
studies
on
immunomodulatory
effects
antiviral
activities
particular
foods
herbs
influenza
virus
coronaviruses
have
been
collated,
with
aim
promoting
use
dietary
herbal
medicine
preventive
therapies,
while
specific
drugs
vaccines
are
yet
discovered
or
still
under
development.
The
volume
existing
reports
irrefutable
evidence
that
possess
a
potential
ability
against
SARS-CoV-2
can
prevent
Foods
could
used
complementary
infection
strengthen
immunity,
agents
masks,
disinfectants
curb
aerosol
transmission,
sanitizing
disinfect
surfaces.
However,
these
hypotheses
need
experimentally
verified
patients.
